Bausch + Lomb launches as a publicly traded company

Print Friendly, PDF & Email

VAUGHAN, Ontario — Bausch + Lomb Corp. launched as a publicly traded company Friday that is focused on protecting and enhancing the gift of sight for millions of people around the world when it began trading under the “BLCO” symbol on the New York Stock Exchange and Toronto Stock Exchange.

“Today marks a tremendous milestone for Bausch + Lomb and an important step forward on the path to an independent company focused on eye health,” said Joseph Papa, chairman and CEO, Bausch + Lomb. “Bausch + Lomb has long been associated with many of the most significant advances in eye health, and I am honored to work alongside our 12,000 global employees as we continue to focus on achieving our ongoing mission of helping people see better to live better all over the world.”

As a fully integrated eye health company, Bausch + Lomb offers a comprehensive portfolio of more than 400 products spanning contact lenses, lens and eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Since its founding in 1853, Bausch + Lomb has been dedicated to advancing eye health for people all over the world, and has pioneered hundreds of innovations, including SofLens, the first mass-produced soft contact lens. Bausch + Lomb’s current portfolio includes market-leading products, such as Biotrue and renu multi-purpose solutions, Biotrue ONEday daily disposable contact lenses, LUMIFY redness reliever eye drops, PreserVision AREDS 2 formula eye vitamin and mineral supplements and VYZULTA (latanoprostene bunod ophthalmic solution), 0.024%.

“Over the course of our company’s nearly two century long history, Bausch + Lomb has always stood at the forefront of cutting-edge scientific and technological optical advancements, and today is no different. We are more focused than ever on developing and offering new treatments to meet unmet eye health needs,” continued Papa.

Bausch + Lomb currently has projects in various stages of pre-clinical and clinical development, including new over-the-counter eye care products, contact lenses, innovative software and prescription medications for myopia management, next-generation cataract and LASIK surgical equipment, premium intraocular lenses, investigational treatments for dry eye and preservative-free formulations of a range of eye drops.

Strong, Experienced Leaders Selected for Board of Directors and Executive Management Team
The Bausch + Lomb Board of Directors, which includes the following individuals, has a balance of strong business and health care experience:

  • Joseph C. Papa, Chairman
  • Thomas W. Ross, Sr., Lead Independent Director
  • Nathalie Bernier
  • Richard U. DeSchutter
  • Sarah B. Kavanagh
  • John A. Paulson
  • Russel C. Robertson
  • Andrew C. von Eschenbach, M.D.

The Bausch + Lomb executive management team includes:

  • Joseph C. Papa, Chairman and CEO
  • Christina Ackermann, Executive Vice President & General Counsel, and President, Ophthalmic Pharmaceuticals
  • Dennis Asharin, Executive Vice President, Chief Global Manufacturing and Supply Chain Officer
  • Sam Eldessouky, Chief Financial Officer
  • Joseph (Joe) Gordon, President, Global Consumer, Surgical and Vision Care
  • Yehia Hashad, M.D., Executive Vice President of Research & Development and Chief Medical Officer
  • Louis Yu, Ph.D., Executive Vice President, Chief Quality Officer
  • Kelly Webber, Executive Vice President, Chief Human Resources Officer

More information, including biographies of the members of the Board of Directors and executive management team and information for investors, can be found on Bausch + Lomb’s updated corporate website, www.bausch.com.


Comments are closed.